Key points are not available for this paper at this time.
< 0.001) than oral administration in alleviating AD symptoms as evidenced by behavioral and histological studies. Thus, VIN in-situ gel can be safe and noninvasive for nose-to-brain drug delivery.
Hard et al. (Wed,) studied this question.